217 related articles for article (PubMed ID: 21119106)
21. Unliganded fibroblast growth factor receptor 1 forms density-independent dimers.
Comps-Agrar L; Dunshee DR; Eaton DL; Sonoda J
J Biol Chem; 2015 Oct; 290(40):24166-77. PubMed ID: 26272615
[TBL] [Abstract][Full Text] [Related]
22. FGFR3 heterodimerization in achondroplasia, the most common form of human dwarfism.
He L; Shobnam N; Wimley WC; Hristova K
J Biol Chem; 2011 Apr; 286(15):13272-81. PubMed ID: 21324899
[TBL] [Abstract][Full Text] [Related]
23. Fluorescent resonance energy transfer imaging of VEGFR dimerization.
Ahmadova Z; Yagublu V; Förg T; Hajiyeva Y; Jesenofsky R; Hafner M; Keese M
Anticancer Res; 2014 May; 34(5):2123-33. PubMed ID: 24778014
[TBL] [Abstract][Full Text] [Related]
24. A Transmembrane Domain GGxxG Motif in CD4 Contributes to Its Lck-Independent Function but Does Not Mediate CD4 Dimerization.
Parrish HL; Glassman CR; Keenen MM; Deshpande NR; Bronnimann MP; Kuhns MS
PLoS One; 2015; 10(7):e0132333. PubMed ID: 26147390
[TBL] [Abstract][Full Text] [Related]
25. Role of dimerization efficiency of transmembrane domains in activation of fibroblast growth factor receptor 3.
Volynsky PE; Polyansky AA; Fakhrutdinova GN; Bocharov EV; Efremov RG
J Am Chem Soc; 2013 Jun; 135(22):8105-8. PubMed ID: 23679838
[TBL] [Abstract][Full Text] [Related]
26. Strong dimerization of wild-type ErbB2/Neu transmembrane domain and the oncogenic Val664Glu mutant in mammalian plasma membranes.
Placone J; He L; Del Piccolo N; Hristova K
Biochim Biophys Acta; 2014 Sep; 1838(9):2326-30. PubMed ID: 24631664
[TBL] [Abstract][Full Text] [Related]
27. The A391E mutation enhances FGFR3 activation in the absence of ligand.
Chen F; Degnin C; Laederich M; Horton WA; Hristova K
Biochim Biophys Acta; 2011 Aug; 1808(8):2045-50. PubMed ID: 21536014
[TBL] [Abstract][Full Text] [Related]
28. High-throughput selection of transmembrane sequences that enhance receptor tyrosine kinase activation.
He L; Hoffmann AR; Serrano C; Hristova K; Wimley WC
J Mol Biol; 2011 Sep; 412(1):43-54. PubMed ID: 21767549
[TBL] [Abstract][Full Text] [Related]
29. Specific inhibition of a pathogenic receptor tyrosine kinase by its transmembrane domain.
He L; Shobnam N; Hristova K
Biochim Biophys Acta; 2011 Jan; 1808(1):253-9. PubMed ID: 20713021
[TBL] [Abstract][Full Text] [Related]
30. Enhanced dimerization drives ligand-independent activity of mutant epidermal growth factor receptor in lung cancer.
Valley CC; Arndt-Jovin DJ; Karedla N; Steinkamp MP; Chizhik AI; Hlavacek WS; Wilson BS; Lidke KA; Lidke DS
Mol Biol Cell; 2015 Nov; 26(22):4087-99. PubMed ID: 26337388
[TBL] [Abstract][Full Text] [Related]
31. Transient dimerization and interaction with ERGIC-53 occur in the fibroblast growth factor receptor 3 early secretory pathway.
Lievens PM; De Servi B; Garofalo S; Lunstrum GP; Horton WA; Liboi E
Int J Biochem Cell Biol; 2008; 40(11):2649-59. PubMed ID: 18577465
[TBL] [Abstract][Full Text] [Related]
32. The transmembrane mutation G380R in fibroblast growth factor receptor 3 uncouples ligand-mediated receptor activation from down-regulation.
Monsonego-Ornan E; Adar R; Feferman T; Segev O; Yayon A
Mol Cell Biol; 2000 Jan; 20(2):516-22. PubMed ID: 10611230
[TBL] [Abstract][Full Text] [Related]
33. Molecular basis for receptor tyrosine kinase A-loop tyrosine transphosphorylation.
Chen L; Marsiglia WM; Chen H; Katigbak J; Erdjument-Bromage H; Kemble DJ; Fu L; Ma J; Sun G; Zhang Y; Liang G; Neubert TA; Li X; Traaseth NJ; Mohammadi M
Nat Chem Biol; 2020 Mar; 16(3):267-277. PubMed ID: 31959966
[TBL] [Abstract][Full Text] [Related]
34. Quantifying the strength of heterointeractions among receptor tyrosine kinases from different subfamilies: Implications for cell signaling.
Paul MD; Grubb HN; Hristova K
J Biol Chem; 2020 Jul; 295(29):9917-9933. PubMed ID: 32467228
[TBL] [Abstract][Full Text] [Related]
35. Differential activation of cysteine-substitution mutants of fibroblast growth factor receptor 3 is determined by cysteine localization.
Adar R; Monsonego-Ornan E; David P; Yayon A
J Bone Miner Res; 2002 May; 17(5):860-8. PubMed ID: 12009017
[TBL] [Abstract][Full Text] [Related]
36. Impaired ligand-dependent MET activation caused by an extracellular SEMA domain missense mutation in lung cancer.
Miao W; Sakai K; Sato H; Imamura R; Jangphattananont N; Takagi J; Nishita M; Minami Y; Matsumoto K
Cancer Sci; 2019 Oct; 110(10):3340-3349. PubMed ID: 31342590
[TBL] [Abstract][Full Text] [Related]
37. Structure of FGFR3 transmembrane domain dimer: implications for signaling and human pathologies.
Bocharov EV; Lesovoy DM; Goncharuk SA; Goncharuk MV; Hristova K; Arseniev AS
Structure; 2013 Nov; 21(11):2087-93. PubMed ID: 24120763
[TBL] [Abstract][Full Text] [Related]
38. Effect of pathogenic cysteine mutations on FGFR3 transmembrane domain dimerization in detergents and lipid bilayers.
You M; Spangler J; Li E; Han X; Ghosh P; Hristova K
Biochemistry; 2007 Oct; 46(39):11039-46. PubMed ID: 17845056
[TBL] [Abstract][Full Text] [Related]
39. Role of receptor tyrosine kinase transmembrane domains in cell signaling and human pathologies.
Li E; Hristova K
Biochemistry; 2006 May; 45(20):6241-51. PubMed ID: 16700535
[TBL] [Abstract][Full Text] [Related]
40. N-glycan on N262 of FGFR3 regulates the intracellular localization and phosphorylation of the receptor.
Hashimoto U; Fujitani N; Uehara Y; Okamoto H; Saitou A; Ito F; Ariki S; Shiratsuchi A; Hasegawa Y; Takahashi M
Biochim Biophys Acta Gen Subj; 2024 Apr; 1868(4):130565. PubMed ID: 38244702
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
